PLx Pharma Inc (PLXP) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of PLx Pharma Inc (NASDAQ:PLXP) from a hold rating to a buy rating in a research report sent to investors on Saturday. The brokerage currently has $7.25 price target on the biotechnology company’s stock.

According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

A number of other brokerages also recently issued reports on PLXP. Redburn Partners raised PLx Pharma to an outperform rating in a report on Tuesday, August 1st. UBS AG raised PLx Pharma from a market perform rating to an outperform rating and set a $12.00 price target for the company in a report on Monday, July 31st. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. PLx Pharma presently has a consensus rating of Buy and a consensus price target of $9.63.

PLx Pharma (NASDAQ:PLXP) remained flat at $6.45 during midday trading on Friday. The company had a trading volume of 23,728 shares. PLx Pharma has a 12 month low of $5.60 and a 12 month high of $142.01. The firm’s 50-day moving average price is $6.51 and its 200-day moving average price is $7.60. The company’s market cap is $56.04 million.

ILLEGAL ACTIVITY WARNING: “PLx Pharma Inc (PLXP) Upgraded to Buy at Zacks Investment Research” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/10/plx-pharma-inc-plxp-upgraded-to-buy-at-zacks-investment-research.html.

In other PLx Pharma news, CFO David Emerson Jorden acquired 32,727 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average cost of $6.88 per share, for a total transaction of $225,161.76. Following the completion of the transaction, the chief financial officer now directly owns 151,913 shares of the company’s stock, valued at $1,045,161.44. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Michael J. Valentino acquired 29,091 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average price of $6.88 per share, with a total value of $200,146.08. Following the completion of the transaction, the insider now directly owns 122,386 shares of the company’s stock, valued at $842,015.68. The disclosure for this purchase can be found here. Insiders acquired 69,091 shares of company stock valued at $475,346 over the last three months. 47.70% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Heritage Way Advisors LLC purchased a new stake in shares of PLx Pharma in the second quarter valued at approximately $197,000. University of Texas Investment Managment Co. purchased a new stake in shares of PLx Pharma in the second quarter valued at approximately $385,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of PLx Pharma in the second quarter valued at approximately $1,413,000. Institutional investors and hedge funds own 19.68% of the company’s stock.

About PLx Pharma

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply